CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-BR-113494-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 24 Jun 2016
Amendment
No
General Information
Brazil
Commercial Release of Bovela® Modified Live Vaccine against Type 1 and Type 2 Bovine Diarrhea Virus
EN
10 Jun 2015
No
Subject of the decision, notification, communication or declaration
  • Decision on Pharmaceuticals (Article 5)
LMO identification & risk assessment
  • BCH-LMO-SCBD-110717-2 Living Modified Organism Bovela® Vaccine
    Boheringer Ingelheim Química e Farmacêutica Ltda. | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-RA-BR-113493-1 Risk Assessment generated by a regulatory process Risk Assessment Bovela® Modified Live Vaccine against Type 1 and Type 2 Bovine Diarrhea Virus
    Bovela® Vaccine | BVDV-1, BVDV-2, Production of medical or pharmaceutical compounds (human or animal)
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter